Research ArticleExperimental Studies

A Gemcitabine Plus 5-Fluorouracil Combination Inhibits Gastric-Cancer Liver Metastasis in a PDOX Model: A Novel Treatment Strategy

NORIHIKO SUGISAWA, HIROTO NISHINO, TAKASHI HIGUCHI, JUN HO PARK, JUN YAMAMOTO, YOSHIHIKO TASHIRO, KEI KAWAGUCHI, MICHAEL BOUVET, MICHIAKI UNNO and ROBERT M. HOFFMAN
Anticancer Research October 2020, 40 (10) 5393-5397; DOI: https://doi.org/10.21873/anticanres.14547

Abstract

Background/Aim: We established a new patient-derived orthotopic xenograft (PDOX) model of gastric cancer liver metastasis and evaluated the efficacy of a novel combination chemotherapy, gemcitabine (GEM) plus 5-fluorouracil (5-FU), compared to a standard regimen of oxaliplatinum (L-OHP) plus 5-FU on the liver metastasis. Materials and Methods: Patient-derived gastric cancer was established in nude mice from the patient' s surgical tumor specimen. A single tumor fragment was implanted in the liver of nude mice. The mice with tumors were treated by GEM plus 5-FU or L-OHP plus 5-FU. Results: GEM plus 5-FU or L-OHP plus 5-FU significantly and similarly inhibited tumor growth on the liver compared to the untreated control (p=0.007, p=0.02, respectively). Conclusion: GEM plus 5-FU could be a novel future clinical alternative to L-OHP plus 5-FU in gastric cancer patients who cannot tolerate platinum drugs.

In gastric-cancer patients, once liver metastasis has appeared, the disease is almost always lethal. Liver metastasis of gastric cancer is mainly treated by systemic chemotherapy since surgical resection is not recommended. Systemic chemotherapy for gastric cancer is still ineffective for long-term survival. Two monoclonal antibodies for programmed cell death protein-1 (PD-1), nivolumab and pembrolizumab, recently showed significant efficacy for gastric-cancer patients in clinical trials (1-4), but immunotherapy is only effective for tumors with microsatellite instability (MSI-H) (4). For most gastric cancer patients, first-line chemotherapy comprises a combination of a fluoropyrimidine [5-fluorouracil (5-FU) or capecitabine] and a platinum drug [cisplatinum (CDDP) or oxaliplatinum (L-OHP)] (5). Both platinum drugs have a limitation for use due to toxicity. CDDP dose-dependently induces nephrotoxicity (6) and ototoxicity (7). L-OHP is less toxic than CDDP; however, L-OHP is not tolerable for some patients due to hypersensitivity reactions (8) and peripheral neuropathy (9). If gastric cancer patients have difficulty with platinum drugs, the patients are treated with 5-FU monotherapy, and if 5-FU fails, a second-line regimen with a taxane (paclitaxel or docetaxel) or irinotecan is used (10).

Gemcitabine (GEM), a synthetic pyrimidine-nucleoside prodrug, is used in various types of cancers, including breast cancer, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and bladder cancer. GEM monotherapy did not show efficacy for gastric-cancer patients in previous trials (11, 12). Combination therapy with GEM and CDDP showed moderate efficacy for gastric cancer in a Phase II trial (13). Currently, there is no combination therapy with GEM recommended for gastric cancer in the clinic.

Orthotopic mouse models of cancer have many advantages over subcutaneous-implant models, which are growing ectopically under the skin (14). Our laboratory pioneered the patient-derived orthotopic xenograft (PDOX) nude-mouse model, which is useful for individualized treatment and precision medicine (15-21). We established the initial PDOX model of gastric cancer in 1993 (22). Our previous studies showed that orthotopic liver-metastasis and PDOX models are suitable models to evaluate drug sensitivity (23, 24).

Figure 1.
Figure 1.

Treatment protocol. The mice were randomized into 3 groups of 9 mice each.

In the present study, we compared the efficacy of the combination of L-OHP or GEM with 5-FU on a liver-metastasis PDOX model of gastric cancer and clarified whether GEM has future clinical potential for metastatic gastric cancer.

Materials and Methods

Mice. Athymic nu/nu nude mice (AntiCancer, Inc., San Diego, CA, USA) were used in this study. Mice were maintained in a barrier facility with high efficiency particulate air (HEPA)-filter at temperature 22°C and 12-h light/dark cycles. Mice were fed an autoclaved laboratory rodent diet ad libitum. Mice were observed on a daily basis and humanely sacrificed by CO2 inhalation if they met humane endpoint criteria: severe tumor burden (more than 20 mm in diameter), prostration, significant body-weight loss, difficulty breathing, rotational motion and body-temperature drop. All experiments were performed under an AntiCancer, Inc. Institutional Animal Care and Use Committee (IACUC) protocol approved for the present study, and the principles and procedures provided in the National Institutes of Health Guide for the Care and Use of Animals under Assurance Number A3873-1 (25).

Patient-derived gastric cancer. A patient diagnosed with poorly-differentiated adenocarcinoma of the stomach underwent gastrectomy in the Department of Surgery, University of California, San Diego (UCSD). A small tumor sample was obtained at the time of the surgical operation and immediately transported to the laboratory on ice. The fresh specimen was implanted into a subcutaneous pocket of nude mice. Written informed consent was provided by the patient as a part of an approved protocol by the Institutional Review Board (IRB) of UCSD.

Surgical implantation of tumor to the liver. A subcutaneous tumor of the patient-derived gastric cancer was harvested and cut into 4 mm3 fragments for surgical implantation. A 15 mm upper-midline incision was made under anesthesia by subcutaneous injection of a 0.02 ml solution of 0.25 mg ketamine, 0.38 mg xylazine, and 0.012 mg acepromazine maleate. The left lobe of liver was gently exposed, and a 7-8 mm vertical incision was made on the middle of left lobe. Then a single tumor fragment was implanted into the liver parenchyma. The wound was closed with a 6-0 nylon suture (AD Surgical, Sunnyvale, CA, USA) after confirming hemostasis (23, 24).

Figure 2.
Figure 2.

Bar graphs show relative tumor volume on day 15 for the untreated control and two treatment groups. Error bars: ±SD. *p<0.05; **p<0.01.

Treatment of gastric-cancer liver metastasis. The mice with growing tumors in the liver were randomized into 3 groups of 9 mice each when the tumor volume reached 100 mm3 and treated as follows for 2 weeks (Figure 1): Group 1 (G1): untreated control; Group 2 (G2): 5-FU (50 mg/kg, intraperitoneal (i.p.) injection, once a week) and L-OHP (6 mg/kg, i.p. injection, once a week); Group 3 (G3): 5-FU (50 mg/kg, i.p. injection, once a week) and GEM (100 mg/kg, i.p. injection, once a week). Tumor length and width were measured with electronic calipers on day 1 and 15. Tumor volume was calculated by the following formula: Tumor volume (mm3)=length (mm) × width (mm) × width (mm) × 1/2. Treatment efficacy was presented as relative tumor volume on day 15 compared to the tumor volume at the beginning of the treatment on day 1. Mouse body weight was measured twice a week. Relative body weight on day 15 compared to the body weight on day 1 was calculated.

Histological examination. All tumors were resected on day 15, and immediately fixed in 10% formalin. The resected tumors were embedded in paraffin, and then hematoxylin and eosin (H&E) staining was performed on 4 μm tissue sections. The H&E-stained slides were observed with a model BH2 microscope (Olympus Corp., Tokyo, Japan).

Statistical analysis. The data are presented as the mean±SD. One-way ANOVA with Tukey's multiple-comparison test was performed to evaluate the differences between the means. p≤0.05 is considered to be statistically significant. Statistical analyses were conducted with GraphPad Prism 7 (GraphPad Software, Inc., San Diego, CA, USA).

Results

A combination of either GEM or L-OHP plus 5-FU inhibited gastric-cancer liver metastasis. The combination of 5-FU and GEM significantly inhibited tumor growth of the liver metastasis on day 15 [relative tumor volume: 2.20±0.76 (mean±SD)] compared to the untreated control [relative tumor volume: 4.13±1.52 (mean±SD)] (p=0.007) (Figure 2). The combination of 5-FU and L-OHP also significantly inhibited the growth of liver metastasis [relative tumor volume: 2.52±1.23 (mean±SD)] compared to the untreated control (p=0.02). There was no significant difference in relative tumor volume between GEM- and L-OHP-treated groups (p=0.84).

Figure 3.
Figure 3.

Efficacy of treatment in the gastric-cancer liver-metastasis PDOX on day 15. (A) Representative images of the liver metastasis (white dotted circle) on day 15 from each group. Scale bars: 10 mm. (B) Representative images of histology with H&E staining on the liver metastasis from each group. Scale bars: 100 μm.

In the untreated control, extensive tumor growth on the liver was observed macroscopically (Figure 3A), and dense proliferation of poorly-differentiated adenocarcinoma cells was observed microscopically in H&E-stained sections (Figure 3B). Decreased tumor growth on the liver was observed macroscopically in both treatment groups of 5-FU plus L-OHP and 5-FU plus GEM, compared to the untreated control (Figure 3A). Both treatment groups decreased the number of adenocarcinoma cells. Necrotic areas were observed microscopically in H&E-stained sections for both treatment groups (Figure 3B).

Effect of treatment on body weight. All mice completed the treatment as scheduled with no obvious side-effects. There was no significant difference in relative body weight on day 15 among the untreated-control [1.04±0.03 (mean±SD)]; 5-FU plus L-OHP [1.01±0.07 (mean±SD)] (p=0.75); and 5-FU plus GEM [1.02±0.02 (mean±SD)] (p=0.85) groups (Figure 4).

Figure 4.
Figure 4.

Bar graphs show relative body weight on day 15 for the untreated-control and two treatment groups. Error bars: ±SD.

Discussion

In the present study, L-OHP or GEM in combination with 5-FU showed similar efficacy to inhibit liver-metastasis growth in a PDOX model of gastric cancer. No obvious side effects were observed with either treatment. The present study indicated that GEM combined with 5-FU can be a promising clinical regimen for liver metastasis of gastric cancer in the future.

The first PDOX model of gastric cancer was developed by our laboratory in 1993, which subsequently showed that the metastasis pattern of patients and PDOX model correlated (22, 26). The present study is the first liver-implantation PDOX model of gastric cancer. The tumor take rate in the liver was 90% allowing sufficient mice to be used for drug-sensitivity testing. The results of the present study indicate that GEM has future clinical potential for metastatic gastric cancer, which would be very valuable for patients who cannot tolerate platinum drugs.

Acknowledgements

This paper is dedicated to the memory of A.R. Moossa, M.D., Sun Lee, M.D., Professor Li Jiaxi, and Masaki Kitajima, M.D.

Footnotes

  • Authors' Contributions

    Conception and design: NS and RMH. Acquisition of data: NS and HN. Analysis and interpretation of data: NS, HN, TH, JHP, JY, YT, KK, MB, MU, and RMH. Writing, review, and/or revision of the manuscript: NS, MU, and RMH.

  • Conflicts of Interest

    The Authors declare that there are no potential conflicts of interest. AntiCancer, Inc. uses PDOX models of cancer for contract research. NS, HN, TH, JHP, JY, YT, and RMH are or were unsalaried associates of AntiCancer, Inc.

  • Received August 9, 2020.
  • Revision received August 27, 2020.
  • Accepted August 28, 2020.

References

  1. ↵
    1. Kang YK,
    2. Boku N,
    3. Satoh T,
    4. Ryu MH,
    5. Chao Y,
    6. Kato K,
    7. Chung HC,
    8. Chen JS,
    9. Muro K,
    10. Kang WK,
    11. Yeh KH,
    12. Yoshikawa T,
    13. Oh SC,
    14. Bai LY,
    15. Tamura T,
    16. Lee KW,
    17. Hamamoto Y,
    18. Kim JG,
    19. Chin K,
    20. Oh DY,
    21. Minashi K,
    22. Cho JY,
    23. Tsuda M,
    24. Chen LT
    : Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390(10111): 2461-2471, 2017. PMID: 28993052. DOI: 10.1016/S0140-6736(17)31827-5
    OpenUrlCrossRefPubMed
    1. Boku N,
    2. Ryu MH,
    3. Kato K,
    4. Chung HC,
    5. Minashi K,
    6. Lee KW,
    7. Cho H,
    8. Kang WK,
    9. Komatsu Y,
    10. Tsuda M,
    11. Yamaguchi K,
    12. Hara H,
    13. Fumita S,
    14. Azuma M,
    15. Chen LT,
    16. Kang YK
    : Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Ann Oncol 30(2): 250-258, 2019. PMID: 30566590. DOI: 10.1093/annonc/mdy540
    OpenUrlPubMed
    1. Shitara K,
    2. Ozguroglu M,
    3. Bang YJ,
    4. Di Bartolomeo M,
    5. Mandala M,
    6. Ryu MH,
    7. Fornaro L,
    8. Olesinski T,
    9. Caglevic C,
    10. Chung HC,
    11. Muro K,
    12. Goekkurt E,
    13. Mansoor W,
    14. McDermott RS,
    15. Shacham-Shmueli E,
    16. Chen X,
    17. Mayo C,
    18. Kang SP,
    19. Ohtsu A,
    20. Fuchs CS,
    21. KEYNOTE-061 Investigators
    : Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet 392(10142): 123-133, 2018. PMID: 29880231. DOI: 10.1016/S0140-6736(18)31257-1
    OpenUrlCrossRefPubMed
  4. ↵
    1. Marabelle A,
    2. Le DT,
    3. Ascierto PA,
    4. Di Giacomo AM,
    5. De Jesus-Acosta A,
    6. Delord JP,
    7. Geva R,
    8. Gottfried M,
    9. Penel N,
    10. Hansen AR,
    11. Piha-Paul SA,
    12. Doi T,
    13. Gao B,
    14. Chung HC,
    15. Lopez-Martin J,
    16. Bang YJ,
    17. Frommer RS,
    18. Shah M,
    19. Ghori R,
    20. Joe AK,
    21. Pruitt SK,
    22. Diaz LA Jr..
    : Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the Phase II KEYNOTE-158 study. J Clin Oncol 38(1): 1-10, 2020. PMID: 31682550. DOI: 10.1200/JCO.19.02105
    OpenUrlPubMed
  5. ↵
    1. Al-Batran SE,
    2. Hartmann JT,
    3. Probst S,
    4. Schmalenberg H,
    5. Hollerbach S,
    6. Hofheinz R,
    7. Rethwisch V,
    8. Seipelt G,
    9. Homann N,
    10. Wilhelm G,
    11. Schuch G,
    12. Stoehlmacher J,
    13. Derigs HG,
    14. Hegewisch-Becker S,
    15. Grossmann J,
    16. Pauligk C,
    17. Atmaca A,
    18. Bokemeyer C,
    19. Knuth A,
    20. Jager E
    : Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26(9): 1435-1442, 2008. PMID: 18349393. DOI: 10.1200/JCO.2007.13.9378
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Pabla N,
    2. Dong Z
    : Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73(9): 994-1007, 2008. PMID: 18272962. DOI: 10.1038/sj.ki.5002786
    OpenUrlCrossRefPubMed
  7. ↵
    1. Karasawa T,
    2. Steyger PS
    : An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol Lett 237(3): 219-227, 2015. PMID: 26101797. DOI: 10.1016/j.toxlet.2015.06.012
    OpenUrlCrossRefPubMed
  8. ↵
    1. Hewitt MR,
    2. Sun W
    : Oxaliplatin-associated hypersensitivity reactions: clinical presentation and management. Clin Colorectal Cancer 6(2): 114-117, 2006. PMID: 16945166. DOI: 10.3816/CCC.2006.n.027
    OpenUrlPubMed
  9. ↵
    1. Griffith KA,
    2. Zhu S,
    3. Johantgen M,
    4. Kessler MD,
    5. Renn C,
    6. Beutler AS,
    7. Kanwar R,
    8. Ambulos N,
    9. Cavaletti G,
    10. Bruna J,
    11. Briani C,
    12. Argyriou AA,
    13. Kalofonos HP,
    14. Yerges-Armstrong LM,
    15. Dorsey SG
    : Oxaliplatin-induced peripheral neuropathy and identification of unique severity groups in colorectal cancer. J Pain Symptom Manage 54(5): 701-706 e701, 2017. PMID: 28743660. DOI: 10.1016/j.jpainsymman.2017.07.033
    OpenUrl
  10. ↵
    1. Hironaka S,
    2. Ueda S,
    3. Yasui H,
    4. Nishina T,
    5. Tsuda M,
    6. Tsumura T,
    7. Sugimoto N,
    8. Shimodaira H,
    9. Tokunaga S,
    10. Moriwaki T,
    11. Esaki T,
    12. Nagase M,
    13. Fujitani K,
    14. Yamaguchi K,
    15. Ura T,
    16. Hamamoto Y,
    17. Morita S,
    18. Okamoto I,
    19. Boku N,
    20. Hyodo I
    : Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 31(35): 4438-4444, 2013. PMID: 24190112. DOI: 10.1200/JCO.2012.48.5805
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Christman K,
    2. Kelsen D,
    3. Saltz L,
    4. Tarassoff PG
    : Phase II trial of gemcitabine in patients with advanced gastric cancer. Cancer 73(1): 5-7, 1994. PMID: 8275437. DOI: 10.1002/1097-0142(19940101)73:1<5::aid-cncr2820730103>3.0.co;2-#
    OpenUrlCrossRefPubMed
  12. ↵
    1. Sessa C,
    2. Aamdal S,
    3. Wolff I,
    4. Eppelbaum R,
    5. Smyth JF,
    6. Sulkes A,
    7. Ten Bokkel Huinink W,
    8. Vermorken J,
    9. Wanders J,
    10. Franklin H,
    11. Verweij J
    : Gemcitabine in patients with advanced malignant melanoma or gastric cancer: phase II studies of the EORTC Early Clinical Trials Group. Ann Oncol 5(5): 471-472, 1994. PMID: 8075055. DOI: 10.1093/oxfordjournals.annonc.a058884
    OpenUrlPubMed
  13. ↵
    1. De Lange SM,
    2. van Groeningen CJ,
    3. Kroep JR,
    4. Van Bochove A,
    5. Snijders JF,
    6. Peters GJ,
    7. Pinedo HM,
    8. Giaccone G
    : Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer. Ann Oncol 15(3): 484-488, 2004. PMID: 14998853. DOI: 10.1093/annonc/mdh109
    OpenUrlCrossRefPubMed
  14. ↵
    1. Hoffman RM
    : Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts. Nat Rev Cancer 15(8): 451-452, 2015. PMID: 26422835. DOI: 10.1038/nrc3972
    OpenUrlCrossRefPubMed
  15. ↵
    1. Fu XY,
    2. Besterman JM,
    3. Monosov A,
    4. Hoffman RM
    : Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. Proc Natl Acad Sci USA 88(20): 9345-9349, 1991. PMID: 1924398.
    OpenUrlAbstract/FREE Full Text
    1. Fu X,
    2. Guadagni F,
    3. Hoffman RM
    : A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc Natl Acad Sci USA 89(12): 5645-5649, 1992. PMID: 1608975.
    OpenUrlAbstract/FREE Full Text
    1. Fu X,
    2. Hoffman RM
    : Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens. Anticancer Res 13(2): 283-286, 1993. PMID: 8517640.
    OpenUrlPubMed
    1. Kawaguchi K,
    2. Igarashi K,
    3. Miyake K,
    4. Kiyuna T,
    5. Miyake M,
    6. Singh AS,
    7. Chmielowski B,
    8. Nelson SD,
    9. Russell TA,
    10. Dry SM,
    11. Li Y,
    12. Unno M,
    13. Singh SR,
    14. Eilber FC,
    15. Hoffman RM
    : Patterns of sensitivity to a panel of drugs are highly individualised for undifferentiated/unclassified soft tissue sarcoma (USTS) in patient-derived orthotopic xenograft (PDOX) nude-mouse models. J Drug Target 27(2): 211-216, 2019. PMID: 30024282. DOI: 10.1080/1061186X.2018.1499748
    OpenUrl
    1. Zhang Z,
    2. Hu K,
    3. Kiyuna T,
    4. Miyake K,
    5. Kawaguchi K,
    6. Igarashi K,
    7. Nelson SD,
    8. Li Y,
    9. Singh SR,
    10. Hoffman RM
    : A patient-derived orthotopic xenograft (PDOX) nude-mouse model precisely identifies effective and ineffective therapies for recurrent leiomyosarcoma. Pharmacol Res 142: 169-175, 2019. PMID: 30807865. DOI: 10.1016/j.phrs.2019.02.021
    OpenUrl
    1. Higuchi T,
    2. Sugisawa N,
    3. Miyake K,
    4. Oshiro H,
    5. Yamamoto N,
    6. Hayashi K,
    7. Kimura H,
    8. Miwa S,
    9. Igarashi K,
    10. Kline Z,
    11. Belt P,
    12. Chawla SP,
    13. Bouvet M,
    14. Singh SR,
    15. Tsuchiya H,
    16. Hoffman RM
    : Combination treatment with sorafenib and everolimus regresses a doxorubicin-resistant osteosarcoma in a pdox mouse model. Anticancer Res 39(9): 4781-4786, 2019. PMID: 31519579. DOI: 10.21873/anticanres.13662
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Zhu G,
    2. Zhao M,
    3. Han Q,
    4. Tan Y,
    5. Sun YU,
    6. Bouvet M,
    7. Singh SR,
    8. Ye J,
    9. Hoffman RM
    : Combination of trabectedin with oxaliplatinum and 5-fluorouracil arrests a primary colorectal cancer in a patient-derived orthotopic xenograft mouse model. Anticancer Res 39(11): 5999-6005, 2019. PMID: 31704825. DOI: 10.21873/anticanres.13805
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Furukawa T,
    2. Fu X,
    3. Kubota T,
    4. Watanabe M,
    5. Kitajima M,
    6. Hoffman RM
    : Nude mouse metastatic models of human stomach cancer constructed using orthotopic implantation of histologically intact tissue. Cancer Res 53(5): 1204-1208, 1993. PMID: 8439965.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Rashidi B,
    2. Gamagami R,
    3. Sasson A,
    4. Sun FX,
    5. Geller J,
    6. Moossa AR,
    7. Hoffman RM
    : An orthotopic mouse model of remetastasis of human colon cancer liver metastasis. Clin Cancer Res 6(6): 2556-2561, 2000. PMID: 10873112.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Oshiro H,
    2. Tome Y,
    3. Kiyuna T,
    4. Yoon SN,
    5. Lwin TM,
    6. Han Q,
    7. Tan Y,
    8. Miyake K,
    9. Higuchi T,
    10. Sugisawa N,
    11. Katsuya Y,
    12. Park JH,
    13. Zang Z,
    14. Razmjooei S,
    15. Bouvet M,
    16. Clary B,
    17. Singh SR,
    18. Kanaya F,
    19. Nishida K,
    20. Hoffman RM
    : Oral recombinant methioninase overcomes colorectal-cancer liver metastasis resistance to the combination of 5-fluorouracil and oxaliplatinum in a patient-derived orthotopic xenograft mouse model. Anticancer Res 39(9): 4667-4671, 2019. PMID: 31519565. DOI: 10.21873/anticanres.13648
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Yang M,
    2. Reynoso J,
    3. Bouvet M,
    4. Hoffman RM
    : A transgenic red fluorescent protein-expressing nude mouse for color-coded imaging of the tumor microenvironment. J Cell Biochem 106(2): 279-284, 2009. PMID: 19097136. DOI: 10.1002/jcb.21999
    OpenUrlCrossRefPubMed
  26. ↵
    1. Furukawa T,
    2. Kubota T,
    3. Watanabe M,
    4. Kitajima M,
    5. Hoffman RM
    : Orthotopic transplantation of histologically intact clinical specimens of stomach cancer to nude mice: correlation of metastatic sites in mouse and individual patient donors. Int J Cancer 53(4): 608-612, 1993. PMID: 8436434.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
A Gemcitabine Plus 5-Fluorouracil Combination Inhibits Gastric-Cancer Liver Metastasis in a PDOX Model: A Novel Treatment Strategy
NORIHIKO SUGISAWA, HIROTO NISHINO, TAKASHI HIGUCHI, JUN HO PARK, JUN YAMAMOTO, YOSHIHIKO TASHIRO, KEI KAWAGUCHI, MICHAEL BOUVET, MICHIAKI UNNO, ROBERT M. HOFFMAN
Anticancer Research Oct 2020, 40 (10) 5393-5397; DOI: 10.21873/anticanres.14547
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords